XmAb 5871

Drug Profile

XmAb 5871

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Fc gamma receptor IIB modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 28 Feb 2018 Xencor has patent protection for XmAb 5871 in USA and other countries worldwide
  • 17 Jan 2018 XmAb 5871 receives Orphan Drug status for Autoimmune disorders in European Union
  • 31 Dec 2017 Xencor completes enrolment in its phase II trial in Systemic lupus erythematosus in USA (IV) in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top